文献速递神经肿瘤

利用数字分析优化Ki-67增殖指数作为脑膜瘤预后生物标志物的应用

Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis.
PubMed 文献 · J Neurosurg · 2024-07-05

该回顾性队列纳入221例原发性脑膜瘤患者(WHO 1级141例、2级64例、3级16例),对所有组织块行Ki-67免疫组化并用QuPath数字定量,比较全切片平均、最佳组织块平均、最大热点等Ki-67指标与病理报告目测值对无复发生存(RFS)和总生存(OS)的预后价值。多变量分析显示全组织块平均Ki-67及病理报告Ki-67与较短RFS相关,而最佳块平均、全切片最大值及最佳块最大热点与RFS无关;仅男性与较短OS独立相关。病理报告Ki-67平均为QuPath平均值的6.5倍。

要点

  • 目测估计的Ki-67显著高估,平均为数字定量全组织块平均值的6.5倍。
  • 全组织块平均Ki-67(每升高1% HR 1.72)与病理报告Ki-67(每升高1% HR 1.05)与较短RFS相关。
  • 最佳块平均、全切片最大及最佳块最大热点Ki-67与RFS无关;Ki-67对OS无预后信息。

核心结论

  • 目测估计显著高估Ki-67,数字定量全组织块平均Ki-67较小热点区域或单个完整组织块提供更多预后信息,Ki-67对OS无预后信息。
  • 作者认为将Ki-67纳入脑膜瘤预后评估的最佳实践包括对多个组织块的平均Ki-67进行数字定量。

研究设计与样本

  • 回顾性队列纳入221例原发性脑膜瘤患者(WHO 1级141例、2级64例、3级16例),所有组织块行Ki-67免疫组化并用自动数字分析软件扫描。
  • 用QuPath量化每张切片的平均Ki-67增殖指数以及每张切片内2.2 mm²区域的Ki-67热点。
  • 由神经病理学家主观定义每例最具代表性的组织块为最佳组织块,病理报告Ki-67由目测估计确定。
  • 检验年龄、性别、WHO分级、切除程度、肿瘤位置和定量Ki-67标记作为RFS和OS的危险因素。

主要发现

  • 多变量分析显示WHO 2级(HR 2.42,p=0.018)、次全切除(HR 8.16,p<0.0001)、近全切除(HR 2.24,p=0.041)、QuPath全组织块平均Ki-67(每升高1% HR 1.72,p=0.030)及病理报告Ki-67(每升高1% HR 1.05,p=0.0026)与较短RFS相关。
  • 最佳组织块平均Ki-67、全切片最大值及最佳组织块最大热点与RFS无关。
  • 仅男性与较短OS独立相关(HR 8.52,p=0.0003)。
  • 病理报告Ki-67平均为QuPath平均值的6.5倍。

关键数值与推荐

  • WHO 2级 vs 其他级别:HR 2.42(p=0.018),与较短RFS相关。
  • 次全切除 vs 全切除:HR 8.16(p<0.0001),与较短RFS相关。
  • 近全切除 vs 全切除:HR 2.24(p=0.041),与较短RFS相关。
  • QuPath全组织块平均Ki-67每升高1%:HR 1.72(p=0.030),与较短RFS相关。
  • 病理报告Ki-67每升高1%:HR 1.05(p=0.0026),与较短RFS相关;男性 vs 女性:HR 8.52(p=0.0003),与较短OS相关。

临床怎么用

  • 作者认为将Ki-67纳入脑膜瘤预后评估的最佳实践包括对多个组织块的平均Ki-67进行数字定量。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ki-67 immunohistochemistry is widely used as a prognostic marker in meningiomas, but visual estimations tend to be imprecise. Whether the average Ki-67 over an entire slide, a particular block, or areas of high staining (hotspots) is prognostic for recurrence-free survival (RFS) and overall survival (OS) is unknown. This study aimed to generate evidence-based recommendations for the optimal use of Ki-67 immunohistochemistry in the workup of meningiomas. METHODS: All tissue blocks from a retrospective cohort of 221 patients with primary meningioma (141 WHO grade 1, 64 WHO grade 2, 16 WHO grade 3) were immunostained for Ki-67 and scanned using automated digital analysis software. QuPath was used to quantify the average Ki-67 proliferation index per slide as well as the Ki-67 hotspot in a 2.2-mm2 area within each slide. The best block was defined subjectively by a neuropathologist as the most representative tissue block from each case. The pathology report Ki-67 was determined by visual estimation. Age, sex, WHO grade, extent of resection, tumor location, and quantitative Ki-67 labeling were tested to determine risk factors for RFS and OS. RESULTS: Multivariable analyses demonstrated that WHO grade 2 (HR 2.42, p = 0.018), subtotal resection (HR 8.16, p < 0.0001), near-total resection (HR 2.24, p = 0.041), QuPath Ki-67 averaged across all blocks (HR per % increase = 1.72, p = 0.030), and pathology report Ki-67 (HR per % increase = 1.05, p = 0.0026) were associated with shorter RFS. The average Ki-67 in the best block, maximum across all slides, and maximum hotspot in the best block were not associated with RFS. Only male sex was independently associated with shorter OS (HR 8.52, p = 0.0003). The pathology report Ki-67 was, on average, 6.5 times higher than the QuPath average. CONCLUSIONS: These data on Ki-67 in meningiomas indicate the following: 1) visual estimation substantially overestimates Ki-67, 2) digital quantification of average Ki-67 across all tissue blocks provides more prognostic information than small hotspot regions or an entire single block, and 3) Ki-67 is not informative for OS. The results suggest that best practices for incorporating Ki-67 into meningioma prognostication include digital quantification of average Ki-67 over multiple blocks.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Thirunavu V, Drumm M, McCord M, et al. Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis. J Neurosurg. 2024. PMID: 38968615. doi:10.3171/2024.4.JNS232857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。